APA (7th ed.) Citation

S, D., I, Š., JP, B., DA, S., MG, M., C, B., . . . MA, D. (2026). Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide-refractory multiple myeloma: Subgroup analysis of the BOSTON trial. British journal of haematology, 208(6), 2260. https://doi.org/10.1111/bjh.70479

Chicago Style (17th ed.) Citation

S, Delimpasi, Špička I, Butler JP, Stevens DA, Mesa MG, Bygrave C, Merlo GM, la Porte C, and Dimopoulos MA. "Benefit of Selinexor Dose Reduction on Outcomes with Selinexor, Bortezomib and Dexamethasone in Patients with Lenalidomide-refractory Multiple Myeloma: Subgroup Analysis Of the BOSTON Trial." British Journal of Haematology 208, no. 6 (2026): 2260. https://doi.org/10.1111/bjh.70479.

MLA (9th ed.) Citation

S, Delimpasi, et al. "Benefit of Selinexor Dose Reduction on Outcomes with Selinexor, Bortezomib and Dexamethasone in Patients with Lenalidomide-refractory Multiple Myeloma: Subgroup Analysis Of the BOSTON Trial." British Journal of Haematology, vol. 208, no. 6, 2026, p. 2260, https://doi.org/10.1111/bjh.70479.